Amaran Biotech Signs MOU with Nippon Fine Chemical for Nanoparticle Drug CDMO Expansion

• Amaran Biotechnology Inc. has signed an MOU with Nippon Fine Chemical Co., Ltd. and Zillion Fine Chemicals International Co., Ltd. to collaborate on nanoparticle-based drug CDMO manufacturing.

• The partnership will leverage Amaran’s aseptic filling capabilities and Nippon Fine Chemical’s phospholipid technology to enhance drug formulation and delivery.

Amaran Biotechnology Inc., a subsidiary of OBI Pharma specializing in CDMO services, has signed a Memorandum of Understanding (MOU) with Japan-based Nippon Fine Chemical Co., Ltd. and its Taiwan subsidiary, Zillion Fine Chemicals International Co., Ltd. The collaboration aims to advance nanoparticle-based drug contract manufacturing while expanding the companies’ market presence in Taiwan, Japan, and globally.

With Taiwan’s first fully automated robotic aseptic filling line, Amaran Biotech provides high-quality, low-waste filling solutions for pharmaceuticals. Nippon Fine Chemical, a company with over 100 years of experience, specializes in phospholipid technology, including the Presome™ series, which improves drug targeting, stability, and controlled release.

Under this agreement, Amaran Biotech will apply its aseptic filling expertise to support Nippon Fine Chemical’s production of nanoparticle-based drugs, including liposomes and lipid nanoparticles (LNPs). The companies will collaborate on sterile filtration, aseptic filling, packaging, storage, and quality management. Zillion Fine Chemicals will contribute its CDMO expertise in Taiwan, reinforcing the alliance’s technological and service capabilities.

Discussing the partnership, Dr. Tessie Che, Chairperson and General Manager of Amaran Biotech, stated: “Amaran continues to follow its motto of ‘Work Locally. Think and Act Globally.’” Ryan Lo, Vice President of Corporate Strategy, Business Development & Regulatory Affairs, emphasized that the collaboration provides a comprehensive CDMO solution for nanoparticle-based drugs. Masaki Matsumoto, Senior General Manager of Nippon Fine Chemical, noted the market’s growth potential and the strategic importance of this partnership for CDMO business expansion in Japan, Taiwan, and beyond